Catastrophic antiphospholipid-antibody syndrome and danazol.
We report a case of catastrophic antiphospholipid-antibody syndrome, with renal and neurological manifestations, which presented shortly after the institution of danazol for the treatment of refractory thrombocytopenia.
Roca
B
B
Infectious and Immunologic Disease Division, Medicine Department, Hospital General of Castellon, Spain. brocav@meditex.es
Ferrer
D
D
Calvo
B
B
D000328:Adult; D000900:Anti-Bacterial Agents; D017152:Antibodies, Antiphospholipid / Q000032:analysis*; D016736:Antiphospholipid Syndrome / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D002388:Catastrophic Illness; D003131:Combined Modality Therapy; D003613:Danazol / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D006435:Renal Dialysis / Q000379:methods; D018570:Risk Assessment; D013921:Thrombocytopenia / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D017152:Antibodies, Antiphospholipid; D003613:Danazol